[["index.html", "ANTARES 1 Abstract 2 Time-tracking", " ANTARES Guillaume Charbonnier 17 June, 2022 1 Abstract Meta-analysis of transcriptomics datasets (microarrays + RNA-Seq) available in the literature for the study of the effect of Fluoxetine in rodents (rat + mouse). Differential expression analysis is produced for each dataset independently, then deregulated genes are converted to their closest human ortholog for cross-specie comparisons with a focus on genes with putative similar response in human. Directed acyclic graph of the ANTARES workflow 2 Time-tracking Summary Detailed Target for current purchase order: 240 hours "],["2-methods-0.html", "3 Methods 3.1 Individual reprocessing of published experiments 3.2 Integration plots 3.3 R session environment", " 3 Methods The methods detailed below correspond to the analyses selected in the article. Some sections in this report correspond to additional analyses. Refer to the source code for details. The analyses were produced using Snakemake (https://doi.org/10.12688/f1000research.29032.1) as workflow manager and R Bookdown for reporting. The source code for all the analyses is available at https://github.com/guillaumecharbonnier/mw-ibrahim2022 and a compiled version of the Bookdown report is available at https://guillaumecharbonnier.github.io/mw-ibrahim2022. 3.1 Individual reprocessing of published experiments 3.1.1 Microarrays Normalized microarrays from seven studies (GSE84185, GSE43261, GSE56028, GSE118669, GSE54307, GSE6476 and GSE42940) were retrieved from GEO using GEOquery (https://doi.org/10.1093/bioinformatics/btm254). One last microarray was retrieved directly from original authors (Surget et al, 2009) and was normalized using RMA from the oligo R package (https://dx.doi.org/10.1093%2Fbioinformatics%2Fbtq431). Microarrays latest annotations were retrieved from Ensembl Biomart on 2021-10-01 for Affymetrix Mouse430_2, Affymetrix Mouse 430A_2, Affymetrix RaGene 1_0_st_v1 and Agilent Sureprint G3_GE_8x60k. When unavailable, annotations from original authors were completed using megablast queries (GSE42940). Probes with mapping to multiple genes were discarded. Differential gene expression analyses were produced with Limma (https://doi.org/10.1093/nar/gkv007). 3.1.2 RNA-Seq Raw reads from four studies (SRP056481, SRP057486, SRP084288 and SRP131063) were retrieved from SRA using sra-tools. Reads were trimmed using sickle (-q 20) (https://github.com/najoshi/sickle#citation) and aligned on GRCm38 (for mouse samples) or Rnor6 (for rat samples) with STAR (https://doi.org/10.1093/bioinformatics/bts635) using default settings. Gene-level counts were produced using subread featureCounts (https://doi.org/10.1093/bioinformatics/btt656) with Ensembl release 102 annotations. Differential gene expression analyses were produced with Deseq2 (https://doi.org/10.1186/s13059-014-0550-8) using apeglm shrinkage (10.1093/bioinformatics/bty895). 3.2 Integration plots To compare differential expression analyses between different experiments, we kept only genes with pvalue below 0.05 and in the top 300 of any compared designs. Plots were produced using R ggplot2 package (https://doi.org/10.1007/978-0-387-98141-3). Gene.stable.ID and Gene.name columns come from Biomart annotations while other gene annotations are from the original authors. As such, incomplete concordance is observed. 3.3 R session environment ## R version 4.0.5 (2021-03-31) ## Platform: x86_64-conda-linux-gnu (64-bit) ## Running under: Ubuntu 20.04.4 LTS ## ## Matrix products: default ## BLAS/LAPACK: /media/gcharbonnier/samsung_m3/miniconda/envs/r_rmd_antares/lib/libopenblasp-r0.3.15.so ## ## locale: ## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C ## [3] LC_TIME=en_DK.UTF-8 LC_COLLATE=en_US.UTF-8 ## [5] LC_MONETARY=en_DK.UTF-8 LC_MESSAGES=en_US.UTF-8 ## [7] LC_PAPER=en_DK.UTF-8 LC_NAME=C ## [9] LC_ADDRESS=C LC_TELEPHONE=C ## [11] LC_MEASUREMENT=en_DK.UTF-8 LC_IDENTIFICATION=C ## ## attached base packages: ## [1] stats4 grid parallel stats graphics grDevices utils ## [8] datasets methods base ## ## other attached packages: ## [1] biomaRt_2.46.3 XML_3.99-0.6 ## [3] ensembldb_2.14.1 AnnotationFilter_1.14.0 ## [5] GenomicFeatures_1.42.3 maptools_1.1-1 ## [7] sp_1.4-5 knitr_1.33 ## [9] R.utils_2.10.1 R.oo_1.24.0 ## [11] R.methodsS3_1.8.1 DT_0.18 ## [13] plyr_1.8.6 umap_0.2.7.0 ## [15] factoextra_1.0.7 ReactomePA_1.34.0 ## [17] enrichplot_1.10.2 clusterProfiler_3.18.1 ## [19] readxl_1.3.1 openxlsx_4.2.3 ## [21] gprofiler2_0.2.0 CEMiTool_1.14.1 ## [23] tximeta_1.8.5 fishpond_1.6.0 ## [25] EnhancedVolcano_1.8.0 apeglm_1.12.0 ## [27] DESeq2_1.30.1 SummarizedExperiment_1.20.0 ## [29] MatrixGenerics_1.2.1 matrixStats_0.58.0 ## [31] edgeR_3.32.1 limma_3.46.0 ## [33] oligo_1.54.1 Biostrings_2.58.0 ## [35] XVector_0.30.0 oligoClasses_1.52.0 ## [37] org.Hs.eg.db_3.12.0 ragene10sttranscriptcluster.db_8.7.0 ## [39] org.Rn.eg.db_3.12.0 mouse4302.db_3.2.3 ## [41] org.Mm.eg.db_3.12.0 AnnotationDbi_1.52.0 ## [43] GEOquery_2.58.0 RColorBrewer_1.1-2 ## [45] GenomicRanges_1.42.0 GenomeInfoDb_1.26.4 ## [47] IRanges_2.24.1 S4Vectors_0.28.1 ## [49] styler_1.4.1 httr_1.4.2 ## [51] dendsort_0.3.4 dendextend_1.15.1 ## [53] circlize_0.4.12 ComplexHeatmap_2.6.2 ## [55] NMF_0.21.0 Biobase_2.50.0 ## [57] BiocGenerics_0.36.0 cluster_2.1.2 ## [59] rngtools_1.5 pkgmaker_0.32.2 ## [61] registry_0.5-1 ggh4x_0.1.2.1 ## [63] ggcorrplot_0.1.3 ggrepel_0.9.1 ## [65] ggbeeswarm_0.6.0 ggpubr_0.4.0 ## [67] ggplot2_3.3.3 yaml_2.2.1 ## [69] pbapply_1.5-0 data.table_1.14.0 ## ## loaded via a namespace (and not attached): ## [1] statnet.common_4.4.1 Hmisc_4.5-0 ## [3] Rsamtools_2.6.0 foreach_1.5.1 ## [5] crayon_1.4.1 MASS_7.3-54 ## [7] backports_1.2.1 impute_1.64.0 ## [9] GOSemSim_2.16.1 rlang_0.4.11 ## [11] intergraph_2.0-2 extrafontdb_1.0 ## [13] extrafont_0.17 BiocParallel_1.24.1 ## [15] rjson_0.2.20 bit64_4.0.5 ## [17] glue_1.4.2 vipor_0.4.5 ## [19] DOSE_3.16.0 haven_2.4.1 ## [21] tidyselect_1.1.1 rio_0.5.26 ## [23] tidyr_1.1.3 proj4_1.0-10.1 ## [25] GenomicAlignments_1.26.0 xtable_1.8-4 ## [27] magrittr_2.0.1 evaluate_0.14 ## [29] zlibbioc_1.36.0 rstudioapi_0.13 ## [31] bslib_0.2.5.1 rpart_4.1-15 ## [33] fastmatch_1.1-0 maps_3.3.0 ## [35] shiny_1.6.0 xfun_0.23 ## [37] askpass_1.1 clue_0.3-59 ## [39] tidygraph_1.2.0 tibble_3.1.2 ## [41] interactiveDisplayBase_1.28.0 ff_4.0.4 ## [43] png_0.1-7 withr_2.4.2 ## [45] rle_0.9.2 bitops_1.0-7 ## [47] ggforce_0.3.3 cellranger_1.1.0 ## [49] pracma_2.3.3 coda_0.19-4 ## [51] pillar_1.6.1 GlobalOptions_0.1.2 ## [53] cachem_1.0.5 graphite_1.36.0 ## [55] GetoptLong_1.0.5 vctrs_0.3.8 ## [57] ellipsis_0.3.2 generics_0.1.0 ## [59] tools_4.0.5 foreign_0.8-81 ## [61] beeswarm_0.3.1 munsell_0.5.0 ## [63] tweenr_1.0.2 fgsea_1.16.0 ## [65] DelayedArray_0.16.3 fastmap_1.1.0 ## [67] compiler_4.0.5 abind_1.4-5 ## [69] httpuv_1.6.1 rtracklayer_1.50.0 ## [71] plotly_4.9.3 GenomeInfoDbData_1.2.4 ## [73] gridExtra_2.3 lattice_0.20-44 ## [75] utf8_1.2.1 later_1.2.0 ## [77] dplyr_1.0.6 BiocFileCache_1.14.0 ## [79] jsonlite_1.7.2 scales_1.1.1 ## [81] graph_1.68.0 carData_3.0-4 ## [83] genefilter_1.72.1 lazyeval_0.2.2 ## [85] promises_1.2.0.1 car_3.0-10 ## [87] doParallel_1.0.16 latticeExtra_0.6-29 ## [89] reticulate_1.20 sna_2.6 ## [91] checkmate_2.0.0 rmarkdown_2.8 ## [93] ash_1.0-15 cowplot_1.1.1 ## [95] forcats_0.5.1 downloader_0.4 ## [97] igraph_1.2.6 survival_3.2-11 ## [99] numDeriv_2016.8-1.1 htmltools_0.5.1.1 ## [101] memoise_2.0.0 locfit_1.5-9.4 ## [103] graphlayouts_0.7.1 viridisLite_0.4.0 ## [105] digest_0.6.27 assertthat_0.2.1 ## [107] mime_0.10 rappdirs_0.3.3 ## [109] Rttf2pt1_1.3.8 emdbook_1.3.12 ## [111] RSQLite_2.2.5 blob_1.2.1 ## [113] preprocessCore_1.52.1 splines_4.0.5 ## [115] Formula_1.2-4 Cairo_1.5-12.2 ## [117] AnnotationHub_2.22.1 ProtGenerics_1.22.0 ## [119] RCurl_1.98-1.3 broom_0.7.6 ## [121] hms_1.1.0 colorspace_2.0-1 ## [123] base64enc_0.1-3 BiocManager_1.30.15 ## [125] shape_1.4.6 affxparser_1.62.0 ## [127] ggrastr_0.2.3 nnet_7.3-16 ## [129] tximport_1.18.0 sass_0.4.0 ## [131] Rcpp_1.0.6 bookdown_0.22 ## [133] mvtnorm_1.1-1 fansi_0.5.0 ## [135] R6_2.5.0 lifecycle_1.0.0 ## [137] zip_2.2.0 curl_4.3.1 ## [139] ggsignif_0.6.1 affyio_1.60.0 ## [141] jquerylib_0.1.4 fastcluster_1.2.3 ## [143] DO.db_2.9 Matrix_1.3-3 ## [145] qvalue_2.22.0 iterators_1.0.13 ## [147] stringr_1.4.0 htmlwidgets_1.5.3 ## [149] polyclip_1.10-0 purrr_0.3.4 ## [151] network_1.16.1 shadowtext_0.0.8 ## [153] reactome.db_1.74.0 openssl_1.4.4 ## [155] htmlTable_2.2.1 bdsmatrix_1.3-4 ## [157] codetools_0.2-18 GO.db_3.12.1 ## [159] gtools_3.9.2 prettyunits_1.1.1 ## [161] dbplyr_2.1.1 RSpectra_0.16-0 ## [163] gridBase_0.4-7 gtable_0.3.0 ## [165] DBI_1.1.1 ggpmisc_0.3.9 ## [167] dynamicTreeCut_1.63-1 KernSmooth_2.23-20 ## [169] stringi_1.6.2 progress_1.2.2 ## [171] reshape2_1.4.4 farver_2.1.0 ## [173] annotate_1.68.0 viridis_0.6.1 ## [175] ggthemes_4.2.4 xml2_1.3.2 ## [177] ggdendro_0.1.22 rvcheck_0.1.8 ## [179] bbmle_1.0.23.1 WGCNA_1.69 ## [181] ggalt_0.4.0 readr_1.4.0 ## [183] geneplotter_1.68.0 BiocVersion_3.12.0 ## [185] bit_4.0.4 scatterpie_0.1.6 ## [187] jpeg_0.1-8.1 ggraph_2.0.5 ## [189] pkgconfig_2.0.3 rstatix_0.7.0 "],["3-results-0.html", "4 Results", " 4 Results Datasets are first explored separately in the two following subsections, then integrative approaches are applied. Note the microarrays are referred to by the GSE id, while the RNA-Seq are referred to by their SRP id. While RNA-Seq also have GSE id, the use of distinct ids make the distinction clearer. "],["3-results-1-Microarray-0.html", "4.1 Microarray datasets", " 4.1 Microarray datasets "],["3-results-1-Microarray-1-GSE84185-1-StressedVsUnstressed-1-DefaultSettings.html", "", " 4.1.1 GSE84185 4.1.1.1 Stressed VS Unstressed 4.1.1.1.1 Default settings ## [1] &quot;Stressed-Unstressed&quot; ## png ## 2 "],["3-results-1-Microarray-1-GSE84185-1-StressedVsUnstressed-2-ForceNormalization.html", "", " 4.1.1.1.2 Force normalization ## [1] &quot;Stressed-Unstressed&quot; ## png ## 2 "],["3-results-1-Microarray-1-GSE84185-2-StressedVsUnstressedInDentateGyrus-1-DefaultSettings.html", "", " 4.1.1.2 Stressed VS Unstressed in Dentate Gyrus 4.1.1.2.1 Default settings ## [1] &quot;Stressed_Dentate_Gyrus-Unstressed_Dentate_Gyrus&quot; ## png ## 2 "],["3-results-1-Microarray-1-GSE84185-2-StressedVsUnstressedInDentateGyrus-2-ForceNormalization.html", "", " 4.1.1.2.2 Force normalization Force normalization is not required since all samples look comparable in boxplots "],["3-results-1-Microarray-1-GSE84185-3-StressedFluoxetineVsStressedAloneInDentateGyrus-1-DefaultSettings.html", "", " 4.1.1.3 Fluoxetine VS Control For Stressed in Dentate Gyrus 4.1.1.3.1 Default settings ## [1] &quot;Stress_Fluoxetine_Dentate_Gyrus-Stress_Alone_Dentate_Gyrus&quot; This heatmap was used to check fold change sign is correct for this design: As manually verified example, we can see FHL2 is overexpressed with Fluoxetine, which can be consistently seen on integration dotplots for the design GSE84185-StressedFluoxetineVsStressedAloneInDentateGyrus. "],["3-results-1-Microarray-1-GSE84185-4-FluoxetineVsControlForNoStressedInDentateGyrus-1-DefaultSettings.html", "", " 4.1.1.4 Fluoxetine VS Control for No Stressed in Dentate Gyrus 4.1.1.4.1 Default settings ## [1] &quot;flxYes-flxNo&quot; This heatmap was used to check fold change sign is correct for this design: As manually verified examples, we can see ASAP1 and ITPA are overexpressed with Fluoxetine, which can be consistently seen on integration dotplots for the design GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus. "],["3-results-1-Microarray-1-GSE84185-5-FluoxetineVsControlForStressedResponderInDentateGyrus-1-DefaultSettings.html", "", " 4.1.1.5 Fluoxetine VS Control for Stressed Responder in Dentate Gyrus 4.1.1.5.1 Default settings ## [1] &quot;flxYes-flxNo&quot; "],["3-results-1-Microarray-1-GSE84185-6-FluoxetineVsControlForStressedNonResponderInDentateGyrus-1-DefaultSettings.html", "", " 4.1.1.6 Fluoxetine VS Control for Stressed NonResponder in Dentate Gyrus 4.1.1.6.1 Default settings ## [1] &quot;flxYes-flxNo&quot; "],["3-results-1-Microarray-2-GSE43261-1-StressedVsUnstressed-1-DefaultSettings.html", "", " 4.1.2 GSE43261 4.1.2.1 Stressed VS Unstressed 4.1.2.1.1 Default settings ## [1] &quot;Stressed_Dentate_Gyrus-Unstressed_Dentate_Gyrus&quot; ## png ## 2 "],["3-results-1-Microarray-2-GSE43261-2-FluoxetineResponderVsControl-1-DefaultSettings.html", "", " 4.1.2.2 Fluoxetine Responder VS Control for Stressed mice 4.1.2.2.1 Default settings ## [1] &quot;treatmentFluoxetine-treatmentuntreated&quot; "],["3-results-1-Microarray-3-GSE56028-1-StressedVsUnstressed-1-DefaultSettings.html", "", " 4.1.3 GSE56028 4.1.3.1 Stressed VS Unstressed 4.1.3.1.1 Default settings ## [1] &quot;Stressed_Dentate_Gyrus-Unstressed_Dentate_Gyrus&quot; "],["3-results-1-Microarray-3-GSE56028-2-FluoxetineVsUntreatedForStressed-1-DefaultSettings.html", "", " 4.1.3.2 Fluoxetine VS Untreated for stressed rats 4.1.3.2.1 Default settings Note that in the table below, &quot;ENSEMBL&quot; and &quot;SYMBOL&quot; correspond to newly annotated probesets, while &quot;Gene.symbol&quot; and &quot;Gene.title&quot; correspond to annotations updated by original authors in GEO. ## [1] &quot;agentfluoxetine-agentuntreated&quot; "],["3-results-1-Microarray-4-GSE118669-1-FluoxetineVsVehicle-1-DefaultSettings.html", "", " 4.1.4 GSE118669 4.1.4.1 Fluoxetine VS Vehicle 4.1.4.1.1 Default settings ## [1] &quot;Fluoxetine-Vehicle&quot; "],["3-results-1-Microarray-5-GSE54307-1-FluoxetineVsOther-1-DefaultSettings.html", "", " 4.1.5 GSE54307 No replicates for this dataset... As a consequence, this dataset is not added to integration plots. 4.1.5.1 Fluoxetine VS Other 4.1.5.1.1 Default settings ## [1] &quot;Other-Fluoxetine&quot; "],["3-results-1-Microarray-5-GSE54307-2-FluoxetineVsVehicle-1-DefaultSettings.html", "", " 4.1.5.2 Fluoxetine VS Vehicle 4.1.5.2.1 Default settings ## [1] &quot;Fluoxetine-Vehicle&quot; "],["3-results-1-Microarray-6-GSE6476-1-FluoxetineVsControl-1-DefaultSettings.html", "", " 4.1.6 GSE6476 4.1.6.1 Stressed VS Unstressed 4.1.6.1.1 Default settings ## [1] &quot;Fluoxetine-Control&quot; "],["3-results-1-Microarray-7-GSE42940-1-FluoxetineVsControl-1-DefaultSettings.html", "", " 4.1.7 GSE42940 Strange normalization centered on 0 and dissimilar signal intensity distribution between samples. Maybe I should go back to CEL files and normalize myself like for Surget 2009? 4.1.7.1 Fluoxetine VS Control 4.1.7.1.1 Default settings ## [1] &quot;Fluoxetine-Control&quot; "],["3-results-1-Microarray-8-Surget2009-1-StressedVsUnstressed-1-DefaultSettings.html", "", " 4.1.8 Surget 2009 4.1.8.1 Stressed VS Unstressed 4.1.8.1.1 Default settings ## [1] &quot;stressS-stressNS&quot; "],["3-results-1-Microarray-8-Surget2009-2-FluoxetineVsSalineForStressedInDentateGyrus-1-DefaultSettings.html", "", " 4.1.8.2 Fluoxetine VS Saline for stressed in Dentate Gyrus 4.1.8.2.1 Default settings ## [1] &quot;treatmentFLX-treatmentSal&quot; "],["3-results-1-Rnaseq-0.html", "4.2 RNA-Seq datasets", " 4.2 RNA-Seq datasets Library strandedeness is evaluated using Salmon with automatic library type detection. Since all samples for each dataset is detected as the same type as the others, automatic library type detection is considered consistent for these datasets and will be trusted. $ grep &quot;Automatically detected most likely library type as&quot; out/salmon/*/*/*/*/*/*/logs/salmon_quant.log | sed &quot;s|/logs/salmon_quant.log.*Automatically detected most likely library type as |\\t|g&quot; out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123954 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123955 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123956 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123957 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123958 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123959 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123960 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123961 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123962 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123963 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123964 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR4123965 ISF out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497505 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497506 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497507 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497508 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497509 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497510 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497511 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497512 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497513 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497514 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497515 IU out/salmon/quant_fastq_pe_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/pe_-t_sanger_-q_20/sra-tools/fastq-dump_pe/SRR6497516 IU out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982298 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982299 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982300 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982301 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982302 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982303 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982304 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982305 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982306 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982307 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982308 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982309 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982310 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982311 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982312 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982313 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982314 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982315 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982316 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982317 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982318 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982319 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982320 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982321 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982322 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982323 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982324 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982325 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982326 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982327 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982328 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982329 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982330 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982331 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982332 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982333 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982334 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982335 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982336 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982337 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982338 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982339 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982340 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982341 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982342 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982343 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982344 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982345 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982346 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982347 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982348 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982349 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982350 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982351 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982352 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982353 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982354 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982355 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982356 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982357 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982358 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982359 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982360 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982361 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982362 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982363 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982364 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982365 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982366 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982367 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982368 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-GRCm38-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1982369 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1927116 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1927117 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1927118 U out/salmon/quant_fastq_se_-l_A_--validateMappings_--numGibbsSamples_20_--gcBias_salmon-index-Rnor6-ensembl-r102/sickle/se_-t_sanger_-q_20/sra-tools/fastq-dump_se/SRR1927119 U "],["3-results-1-Rnaseq-1-SRP056481-0.html", "", " 4.2.1 SRP056481 "],["3-results-1-Rnaseq-1-SRP056481-3-DEA-1-FluoxetineVsMethylcellulose-1-Apeglm.html", "", " 4.2.1.1 DEA 4.2.1.1.1 Fluoxetine VS Methylcellulose 4.2.1.1.1.1 Apeglm shrinkage ## [1] &quot;Intercept&quot; ## [2] &quot;treatment_Fluoxetine_vs_Methylcellulose&quot; Figure 4.1: Volcano plot. 6 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here No Enrichr results for downregulated genes because there are none g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here No g:Profiler results for downregulated genes because there are none g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP056481-3-DEA-1-FluoxetineVsMethylcellulose-2-Ashr.html", "", " 4.2.1.1.1.2 Ashr shrinkage ## [1] &quot;Intercept&quot; ## [2] &quot;treatment_Fluoxetine_vs_Methylcellulose&quot; Figure 4.2: Volcano plot. 0 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. No Enrichr results for deregulated genes because there are none No Enrichr results for upregulated genes because there are none No Enrichr results for downregulated genes because there are none No g:Profiler results for deregulated genes because there are none No g:Profiler results for upregulated genes because there are none No g:Profiler results for downregulated genes because there are none "],["3-results-1-Rnaseq-1-SRP056481-3-DEA-1-FluoxetineVsMethylcellulose-3-Normal.html", "", " 4.2.1.1.1.3 Normal shrinkage ## [1] &quot;Intercept&quot; ## [2] &quot;treatment_Fluoxetine_vs_Methylcellulose&quot; Figure 4.3: Volcano plot. 0 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. No Enrichr results for deregulated genes because there are none No Enrichr results for upregulated genes because there are none No Enrichr results for downregulated genes because there are none No g:Profiler results for deregulated genes because there are none No g:Profiler results for upregulated genes because there are none No g:Profiler results for downregulated genes because there are none "],["3-results-1-Rnaseq-1-SRP056481-3-DEA-1-FluoxetineVsMethylcellulose-4-NormalLowerFCThreshold.html", "", " 4.2.1.1.1.4 Normal shrinkage with lower FC Threshold ## [1] &quot;Intercept&quot; ## [2] &quot;treatment_Fluoxetine_vs_Methylcellulose&quot; Figure 4.4: Volcano plot. 39 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.2 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP056481-4-IsoformQuant.html", "", " 4.2.1.2 Isoform quantification TPM and isoform proportions results are available here. ## Progress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 "],["3-results-1-Rnaseq-1-SRP056481-5-DTU-1-FluoxetineVsMethylcellulose.html", "", " 4.2.1.3 DTU 4.2.1.3.1 Fluoxetine VS Methylcellulose ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 24 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 24 ## ## FALSE TRUE ## 6845 13 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSRNOT00000080683 -0.1029960 0.00320513 ## ENSRNOT00000085263 -0.0992650 0.00320513 ## ENSRNOT00000018237 -0.0867117 0.00320513 ## ENSRNOT00000084120 -0.0857084 0.00320513 ## ENSRNOT00000015453 -0.0765245 0.00320513 ## ENSRNOT00000008886 0.0660385 0.00320513 ## sign.lfc ## sig -1 0 1 ## FALSE 3432 7 3406 ## TRUE 7 0 6 Figure 4.5: Top upregulated isoforms Figure 4.6: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.7: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.8: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.9: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.10: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.11: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP057486-0.html", "", " 4.2.2 SRP057486 "],["3-results-1-Rnaseq-1-SRP057486-1-PCA.html", "", " 4.2.2.1 PCA ## [1] &quot;Intercept&quot; &quot;tissue_Brain.BLA_vs_Brain.ACC&quot; ## [3] &quot;tissue_Brain.CA1_vs_Brain.ACC&quot; &quot;tissue_Brain.CeA_vs_Brain.ACC&quot; ## [5] &quot;tissue_Brain.NAc_vs_Brain.ACC&quot; &quot;tissue_Brain.PrL_vs_Brain.ACC&quot; ## [7] &quot;treatment_Shocked_vs_Non.Shocked&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; "],["3-results-1-Rnaseq-1-SRP057486-2-UMAP.html", "", " 4.2.2.2 UMAP ## [1] &quot;TODO&quot; "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-1-FluoxetineVsVehicleWithTissueAndTreatmentAsCovariates-1-Apeglm.html", "", " 4.2.2.3 DEA 4.2.2.3.1 Fluoxetine VS Vehicle with Tissue and Treatment as covariates 4.2.2.3.1.1 Apgelm shrinkage ## [1] &quot;Intercept&quot; &quot;tissue_Brain.BLA_vs_Brain.ACC&quot; ## [3] &quot;tissue_Brain.CA1_vs_Brain.ACC&quot; &quot;tissue_Brain.CeA_vs_Brain.ACC&quot; ## [5] &quot;tissue_Brain.NAc_vs_Brain.ACC&quot; &quot;tissue_Brain.PrL_vs_Brain.ACC&quot; ## [7] &quot;treatment_Shocked_vs_Non.Shocked&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.12: Volcano plot. 224 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-1-FluoxetineVsVehicleWithTissueAndTreatmentAsCovariates-2-Normal.html", "", " 4.2.2.3.1.2 Normal shrinkage ## [1] &quot;Intercept&quot; &quot;tissue_Brain.BLA_vs_Brain.ACC&quot; ## [3] &quot;tissue_Brain.CA1_vs_Brain.ACC&quot; &quot;tissue_Brain.CeA_vs_Brain.ACC&quot; ## [5] &quot;tissue_Brain.NAc_vs_Brain.ACC&quot; &quot;tissue_Brain.PrL_vs_Brain.ACC&quot; ## [7] &quot;treatment_Shocked_vs_Non.Shocked&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.13: Volcano plot. 0 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. No Enrichr results for deregulated genes because there are none No Enrichr results for upregulated genes because there are none No Enrichr results for downregulated genes because there are none No g:Profiler results for deregulated genes because there are none No g:Profiler results for upregulated genes because there are none No g:Profiler results for downregulated genes because there are none "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-2-FluoxetineVsVehicleForBrainCA1SubsetWithTreatmentAsCovariates-1-Apeglm.html", "", " 4.2.2.3.2 Fluoxetine VS Vehicle for Brain CA1 subset with Treatment as covariate 4.2.2.3.2.1 Apeglm shrinkage ## [1] &quot;Intercept&quot; &quot;treatment_Shocked_vs_Non.Shocked&quot; ## [3] &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.14: Volcano plot. 41 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-2-FluoxetineVsVehicleForBrainCA1SubsetWithTreatmentAsCovariates-2-Normal.html", "", " 4.2.2.3.2.2 Normal shrinkage ## [1] &quot;Intercept&quot; &quot;treatment_Shocked_vs_Non.Shocked&quot; ## [3] &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.15: Volcano plot. 0 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. No Enrichr results for deregulated genes because there are none No Enrichr results for upregulated genes because there are none No Enrichr results for downregulated genes because there are none No g:Profiler results for deregulated genes because there are none No g:Profiler results for upregulated genes because there are none No g:Profiler results for downregulated genes because there are none "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-3-FluoxetineVsVehicleForBrainCA1Shocked-1-Apeglm.html", "", " 4.2.2.3.3 Fluoxetine VS Vehicle for Brain CA1 and Stressed subset 4.2.2.3.3.1 Apeglm shrinkage ## [1] &quot;Intercept&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.16: Volcano plot. 20 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-3-FluoxetineVsVehicleForBrainCA1Shocked-2-Normal.html", "", " 4.2.2.3.3.2 Normal shrinkage ## [1] &quot;Intercept&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.17: Volcano plot. 1 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here No Enrichr results for upregulated genes because there are none Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here No g:Profiler results for upregulated genes because there are none g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-4-FluoxetineVsVehicleForBrainCA1NonShocked-1-Apeglm.html", "", " 4.2.2.3.4 Fluoxetine VS Vehicle for Brain CA1 and non-shocked 4.2.2.3.4.1 Apeglm shrinkage ## [1] &quot;Intercept&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.18: Volcano plot. 308 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-3-DEA-4-FluoxetineVsVehicleForBrainCA1NonShocked-2-Normal.html", "", " 4.2.2.3.4.2 Normal shrinkage ## [1] &quot;Intercept&quot; &quot;drug_Fluoxetine_vs_Vehicle&quot; Figure 4.19: Volcano plot. 137 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP057486-4-IsoformQuant.html", "", " 4.2.2.4 Isoform quantification TPM and isoform proportions results are available here. ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 "],["3-results-1-Rnaseq-1-SRP057486-5-DTU-1-FluoxetineVsVehicle.html", "", " 4.2.2.5 DTU 4.2.2.5.1 Fluoxetine VS Vehicle ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE TRUE ## 54294 2 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSMUST00000098817 -0.0135554 0.010000 ## ENSMUST00000029448 0.0611906 0.045000 ## ENSMUST00000156211 -0.0148871 0.110000 ## ENSMUST00000021567 -0.0128537 0.138000 ## ENSMUST00000238390 0.0106139 0.138000 ## ENSMUST00000074575 -0.0160573 0.151429 ## sign.lfc ## sig -1 0 1 ## FALSE 24684 5 29605 ## TRUE 1 0 1 Figure 4.20: Top upregulated isoforms Figure 4.21: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.22: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.23: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.24: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.25: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.26: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP057486-5-DTU-2-FluoxetineVsVehicleForBrainCA1SubsetWithTreatmentAsCovariate.html", "", " 4.2.2.5.2 Fluoxetine VS Vehicle for Brain CA1 subset with Treatment as covariate ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE ## 38378 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSMUST00000102780 -0.0789515 0.77875 ## ENSMUST00000042161 -0.0721868 0.77875 ## ENSMUST00000151952 0.0679677 0.77875 ## ENSMUST00000179041 -0.0618825 0.77875 ## ENSMUST00000035797 0.0423860 0.77875 ## ENSMUST00000029257 0.0407517 0.77875 ## sign.lfc ## sig -1 0 1 ## FALSE 19432 17 18929 Figure 4.27: Top upregulated isoforms Figure 4.28: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.29: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.30: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.31: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.32: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.33: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP057486-5-DTU-3-FluoxetineVsVehicleForBrainCA1SubsetShocked.html", "", " 4.2.2.5.3 Fluoxetine VS Vehicle for Brain CA1 shocked subset ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE TRUE ## 32605 2 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSMUST00000087258 0.0949678 0.005000 ## ENSMUST00000040325 0.0858325 0.005000 ## ENSMUST00000164225 -0.0649914 0.680000 ## ENSMUST00000140551 0.1246691 0.725385 ## ENSMUST00000139064 -0.1231062 0.725385 ## ENSMUST00000112709 -0.0911706 0.725385 ## sign.lfc ## sig -1 0 1 ## FALSE 15919 27 16659 ## TRUE 0 0 2 Figure 4.34: Top upregulated isoforms Figure 4.35: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.36: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.37: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.38: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.39: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.40: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP057486-5-DTU-4-FluoxetineVsVehicleForBrainCA1NonShocked.html", "", " 4.2.2.5.4 Fluoxetine VS Vehicle for Brain CA1 NonShocked subset ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE TRUE ## 33014 5 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSMUST00000034175 -0.1888482 0.002000 ## ENSMUST00000179721 0.1849630 0.002000 ## ENSMUST00000036453 -0.0535686 0.002000 ## ENSMUST00000107601 -0.0442325 0.002000 ## ENSMUST00000102911 0.0401357 0.002000 ## ENSMUST00000030125 0.1644108 0.433448 ## sign.lfc ## sig -1 0 1 ## FALSE 16755 23 16236 ## TRUE 3 0 2 Figure 4.41: Top upregulated isoforms Figure 4.42: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.43: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.44: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.45: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.46: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.47: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP084288-0.html", "", " 4.2.3 SRP084288 "],["3-results-1-Rnaseq-1-SRP084288-1-PCA.html", "", " 4.2.3.1 PCA ## [1] &quot;Intercept&quot; ## [2] &quot;tissue_region_Hippocampus_vs_Frontal.cortex&quot; ## [3] &quot;tissue_region_Pituitary.gland_vs_Frontal.cortex&quot; ## [4] &quot;group_Fluoxetine_vs_Control&quot; ## [5] &quot;group_Acupuncture_vs_Control&quot; ## [6] &quot;group_model.of.depression_vs_Control&quot; "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-1-FluoxetineVsControlWithTissueAsCovariate-1-Apeglm.html", "", " 4.2.3.2 DEA 4.2.3.2.1 Fluoxetine VS Control with Tissue as covariate 4.2.3.2.1.1 Apeglm shrinkage ## [1] &quot;Intercept&quot; ## [2] &quot;tissue_region_Hippocampus_vs_Frontal.cortex&quot; ## [3] &quot;tissue_region_Pituitary.gland_vs_Frontal.cortex&quot; ## [4] &quot;group_Fluoxetine_vs_Control&quot; ## [5] &quot;group_Acupuncture_vs_Control&quot; ## [6] &quot;group_model.of.depression_vs_Control&quot; Figure 4.48: Volcano plot. 104 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here This heatmap was used to check fold change sign is correct for this design: We can see ASAP1 is overexpressed with Fluoxetine, which can be consistently seen on integration dotplots for the design GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus. "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-1-FluoxetineVsControlWithTissueAsCovariate-2-Normal.html", "", " 4.2.3.2.1.2 Normal shrinkage ## [1] &quot;Intercept&quot; ## [2] &quot;tissue_region_Hippocampus_vs_Frontal.cortex&quot; ## [3] &quot;tissue_region_Pituitary.gland_vs_Frontal.cortex&quot; ## [4] &quot;group_Fluoxetine_vs_Control&quot; ## [5] &quot;group_Acupuncture_vs_Control&quot; ## [6] &quot;group_model.of.depression_vs_Control&quot; Figure 4.49: Volcano plot. 13 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here This heatmap was used to check fold change sign is correct for this design: We can see ASAP1 is overexpressed with Fluoxetine, which can be consistently seen on integration dotplots for the design GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus. "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-2-FluoxetineVsControlInHyppocampus.html", "", " 4.2.3.2.2 Fluoxetine VS Control in Hippocampus ## 0% 25% 50% 75% 100% ## -5.97727992 -0.36725562 -0.17074236 0.03242148 5.67242534 "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-3-FluoxetineVsModelOfDepressionWithTissueAsCovariate-1-Apeglm.html", "", " 4.2.3.2.3 Fluoxetine VS ModelOfDepression with Tissue as covariate 4.2.3.2.3.1 Apeglm shrinkage Figure 4.50: Volcano plot. 66 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-3-FluoxetineVsModelOfDepressionWithTissueAsCovariate-2-Normal.html", "", " 4.2.3.2.3.2 Normal shrinkage Figure 4.51: Volcano plot. 13 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP084288-3-DEA-4-FluoxetineVsModelOfDepressionInHyppocampus.html", "", " 4.2.3.2.4 Fluoxetine VS ModelOfDepression in Hippocampus ## 0% 25% 50% 75% 100% ## -5.20945337 -0.41503750 -0.21820507 -0.03952836 3.16992500 "],["3-results-1-Rnaseq-1-SRP084288-4-IsoformQuant.html", "", " 4.2.3.3 Isoform quantification TPM and isoform proportions results are available here. ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 "],["3-results-1-Rnaseq-1-SRP084288-5-DTU-1-FluoxetineVsControlWithTissueAsCovariate.html", "", " 4.2.3.4 DTU 4.2.3.4.1 Fluoxetine VS Control Note that contrary to DEA, it is not possible to use the tissue_region covariate in the differential design. Hence the sample from the three tissue regions are considered as biological replicate in this section. ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE ## 6070 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSRNOT00000082627 -0.1225261 0.465 ## ENSRNOT00000016083 0.1212046 0.465 ## ENSRNOT00000091574 0.0452601 0.465 ## ENSRNOT00000041891 -0.0391653 0.465 ## ENSRNOT00000063787 -0.0313036 0.698 ## ENSRNOT00000012022 0.0509958 0.790 ## sign.lfc ## sig -1 0 1 ## FALSE 3022 14 3034 Figure 4.52: Top upregulated isoforms Figure 4.53: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.54: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.55: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.56: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.57: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.58: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP084288-5-DTU-2-FluoxetineVsModelOfDepressionWithTissueAsCovariate.html", "", " 4.2.3.4.2 Fluoxetine VS ModelOfDepression Note that contrary to DEA, it is not possible to use the tissue_region covariate in the differential design. Hence the sample from the three tissue regions are considered as biological replicate in this section. ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE TRUE ## 6041 1 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSRNOT00000061114 0.0612122 0.010000 ## ENSRNOT00000083046 -0.1311414 0.967415 ## ENSRNOT00000085609 0.1279302 0.967415 ## ENSRNOT00000093353 -0.1175006 0.967415 ## ENSRNOT00000024067 -0.1068605 0.967415 ## ENSRNOT00000023431 -0.1009479 0.967415 ## sign.lfc ## sig -1 0 1 ## FALSE 2932 12 3097 ## TRUE 0 0 1 Figure 4.59: Top upregulated isoforms Figure 4.60: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.61: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.62: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.63: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.64: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.65: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP084288-6-CheckSex.html", "", " 4.2.3.5 Check Sex Before doing the analysis on this dataset, we want to check the sex of these samples. "],["3-results-1-Rnaseq-1-SRP131063-0.html", "", " 4.2.4 SRP131063 "],["3-results-1-Rnaseq-1-SRP131063-3-DEA-1-FluoxetineVsSaline-1-Apeglm.html", "", " 4.2.4.1 DEA 4.2.4.1.1 Fluoxetine VS Saline for Stressed 4.2.4.1.1.1 Apeglm ## [1] &quot;Intercept&quot; ## [2] &quot;group_stress.fluoxetine_vs_stress.saline&quot; ## [3] &quot;group_stress.albiflorin_vs_stress.saline&quot; ## [4] &quot;group_control.saline_vs_stress.saline&quot; Figure 4.66: Volcano plot. 120 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here Enrichr results for downregulated genes are available here g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here g:Profiler results for all downregulated genes are available here g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP131063-3-DEA-1-FluoxetineVsSaline-2-Normal.html", "", " 4.2.4.1.1.2 Normal ## [1] &quot;Intercept&quot; ## [2] &quot;group_stress.fluoxetine_vs_stress.saline&quot; ## [3] &quot;group_stress.albiflorin_vs_stress.saline&quot; ## [4] &quot;group_control.saline_vs_stress.saline&quot; Figure 4.67: Volcano plot. 1 significant genes according to Pvalue &lt; 0.05 and |log2FoldChange| &gt; 0.5 are highlighted in red and available in this table. Enrichr results for all deregulated genes are available here Enrichr results for upregulated genes are available here No Enrichr results for downregulated genes because there are none g:Profiler results for all deregulated genes are available here g:Profiler results for all upregulated genes are available here No g:Profiler results for downregulated genes because there are none g:Profiler results for comparison of the three queries above are available here "],["3-results-1-Rnaseq-1-SRP131063-4-IsoformQuant.html", "", " 4.2.4.2 Isoform quantification TPM and isoform proportions results are available here. ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 20 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 20 "],["3-results-1-Rnaseq-1-SRP131063-5-DTU-1-FluoxetineVsSaline.html", "", " 4.2.4.3 DTU 4.2.4.3.1 Fluoxetine VS Methylcellulose ## \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 1 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 2 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 3 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 4 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 5 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 6 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 7 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 8 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 9 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 10 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 11 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 12 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 13 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 14 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 15 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 16 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 17 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 18 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 19 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 20 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 21 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 22 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 23 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 24 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 25 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 26 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 27 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 28 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 29 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 30 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 31 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 32 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 33 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 34 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 35 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 36 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 37 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 38 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 39 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 40 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 41 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 42 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 43 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 44 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 45 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 46 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 47 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 48 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 49 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 50 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 51 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 52 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 53 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 54 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 55 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 56 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 57 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 58 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 59 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 60 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 61 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 62 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 63 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 64 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 65 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 66 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 67 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 68 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 69 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 70 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 71 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 72 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 73 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 74 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 75 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 76 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 77 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 78 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 79 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 80 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 81 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 82 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 83 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 84 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 85 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 86 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 87 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 88 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 89 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 90 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 91 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 92 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 93 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 94 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 95 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 96 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 97 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 98 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 99 on 100 \b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\b\bProgress: 100 on 100 ## ## FALSE TRUE ## 7597 5 ## DataFrame with 6 rows and 2 columns ## log2FC qvalue ## &lt;numeric&gt; &lt;numeric&gt; ## ENSRNOT00000010308 0.0729439 0.002000 ## ENSRNOT00000084530 0.0500894 0.002000 ## ENSRNOT00000027677 -0.0472291 0.002000 ## ENSRNOT00000015325 -0.0470160 0.002000 ## ENSRNOT00000015152 0.0463497 0.002000 ## ENSRNOT00000092477 -0.0901001 0.158571 ## sign.lfc ## sig -1 0 1 ## FALSE 3697 10 3890 ## TRUE 2 0 3 Figure 4.68: Top upregulated isoforms Figure 4.69: Top downregulated isoforms The complete table for all transcripts passing the labelKeep default filter is available here. Figure 4.70: Distribution of inferential replicates for the top upregulated isoform, for each sample, splitted by condition Figure 4.71: Distribution of inferential replicates for the top downregulated isoform, for each sample, splitted by condition Figure 4.72: TPM, isoform proportion and raw counts for the top upregulated isoform, for each sample, splitted by condition Figure 4.73: TPM, isoform proportion and raw counts for the top downregulated isoform, for each sample, splitted by condition Figure 4.74: MA-plot with blue-highlighted genes corresponding to those with qvalue &lt; 0.1 "],["3-results-1-Rnaseq-1-SRP131063-6-CheckSex.html", "", " 4.2.4.4 Check Sex Before doing the analysis on this dataset, we want to check the sex of these samples. "],["3-results-1-Rnaseq-2-CheckSexControl.html", "", " 4.2.5 Check Sex Control (GSE195833) The raw counts table from the GSE195833 study was retrieved to highlight how the signal for sexual genes should vary in an experiment with both male and female. Note that the table was quantified at transcript level instead of gene one, hence the multiple rows for the same gene name. Eif2s3y seems to be the best discriminant for male VS female. Since it does not vary between samples for SRP131063 and SRP084288, and its vst signal is above 10 for all samples, we can reasonably conclude all the samples are males. "],["3-results-3-Integration-0.html", "4.3 Integration", " 4.3 Integration Integration analyses are done in this section following designs specified by El Chrif. Analyses were first done using the closest human ortholog (Section 4.3.1). For microarrays, mapping from probes or probesets to genes were done using the original author annotations, completed with available R Org.db modules. Analyses were then repeated using the original Gene name for rat or mouse (Section 4.3.2). For microarrays, mapping from probes or probesets to genes were done using Biomart latest annotations, or using megablast queries when unavailable (GSE42940). Probes with mapping to multiple genes are discarded. For RNA-Seq, log2FoldChange use in this integration section is the Normal shrinkage and not the Apeglm that was considered too stringent for this kind of analysis. "],["3-results-3-Integration-1-ToHumanOrtholog-1-MouseFluoxetineVsControlForStressed.html", "", " 4.3.1 To closest human ortholog 4.3.1.1 Mouse Fluoxetine VS Control for Stressed in Dentate Gyrus This section corresponds to the first meta-analysis requested by El Chrif. Table 4.1: Mapping between ids and designs used in the integration plots below id design 1-GSE43261 GSE43261-FluoxetineResponderVsControl 2-GSE84185 GSE84185-FluoxetineVsControlForStressedResponderInDentateGyrus 3-GSE84185 GSE84185-StressedFluoxetineVsStressedAloneInDentateGyrus 4-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 5-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.75: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.76: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.77: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-2-RatFluoxetineVsControlForStressed.html", "", " 4.3.1.2 Rat Stress Alone VS Stress Fluoxetine in Dentate Gyrus This section corresponds to the second meta-analysis requested by El Chrif. Table 4.2: Mapping between ids and designs used in the integration plots below id design 1-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 2-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 3-SRP131063 SRP131063-FluoxetineVsSalineForStressed Figure 4.78: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.79: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.80: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-3-RatMouseFluoxetineVsControlForStressed.html", "", " 4.3.1.3 Rat+Mouse Fluoxetine VS Control for Stressed in Dentate Gyrus This section corresponds to the first+second meta-analysis requested by El Chrif. Table 4.3: Mapping between ids and designs used in the integration plots below id design 1-GSE43261 GSE43261-FluoxetineResponderVsControl 2-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 3-GSE84185 GSE84185-StressedFluoxetineVsStressedAloneInDentateGyrus 4-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 5-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 6-SRP131063 SRP131063-FluoxetineVsSalineForStressed 7-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.81: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.82: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.83: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-4-MouseFluoxetineVsControlForNoStressed.html", "", " 4.3.1.4 Mouse Fluoxetine VS Control for NoStressed in Dentate Gyrus This section corresponds to the third meta-analysis requested by El Chrif. Note GSE54307 is only a 1 VS 1 comparison. Table 4.4: Mapping between ids and designs used in the integration plots below id design 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE54307 GSE54307-FluoxetineVsVehicle 3-GSE6476 GSE6476-FluoxetineVsControl 4-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 5-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked Figure 4.84: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.85: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.86: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-5-RatFluoxetineVsControlForNoStressed.html", "", " 4.3.1.5 Rat Fluoxetine VS Control for NoStressed in Dentate Gyrus This section corresponds to the fourth meta-analysis requested by El Chrif. Table 4.5: Mapping between ids and designs used in the integration plots below id design 1-GSE42940 GSE42940-FluoxetineVsControl 2-SRP056481 SRP056481-FluoxetineVsMethylcellulose Figure 4.87: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.88: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.89: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-6-RatMouseFluoxetineVsControlForNoStressed.html", "", " 4.3.1.6 Rat+Mouse Fluoxetine VS Control for NoStressed in Dentate Gyrus Table 4.6: Mapping between ids and designs used in the integration plots below id design 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE42940 GSE42940-FluoxetineVsControl 3-GSE54307 GSE54307-FluoxetineVsVehicle 4-GSE6476 GSE6476-FluoxetineVsControl 5-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 6-SRP056481 SRP056481-FluoxetineVsMethylcellulose 7-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked Figure 4.90: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.91: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.92: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-1-ToHumanOrtholog-7-RatMouseFluoxetineVsControlForStressedAndNoStress.html", "", " 4.3.1.7 Rat+Mouse Fluoxetine VS Control for Stressed and no stressed in Dentate Gyrus This section corresponds to the 4 meta-analysis requested by El Chrif. Table 4.7: Mapping between ids and designs used in the integration plots below id design 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE42940 GSE42940-FluoxetineVsControl 3-GSE43261 GSE43261-FluoxetineResponderVsControl 4-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 5-GSE6476 GSE6476-FluoxetineVsControl 6-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 7-GSE84185 GSE84185-StressedFluoxetineVsStressedAloneInDentateGyrus 8-SRP056481 SRP056481-FluoxetineVsMethylcellulose 9-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked 10-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 11-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 12-SRP131063 SRP131063-FluoxetineVsSalineForStressed 13-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.93: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.94: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Figure 4.95: Consensus-sorted genes significant in at least one comparison (padj &lt; 0.0001). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-1-MouseFluoxetineVsControlForStressed.html", "", " 4.3.2 Using original specie Gene.name In this section, integration analysis are done without conversion to human ortholog. Conversion from mouse to rat or vice-versa is irrelevant because Gene.name are mostly shared, and when they are not, there is no ortholog available for conversion. 4.3.2.1 Mouse Fluoxetine VS Control for Stressed in Dentate Gyrus This section corresponds to the first meta-analysis requested by El Chrif. Table 4.8: Mapping between ids and designs used in the integration plots below id design 1-GSE43261 GSE43261-FluoxetineResponderVsControl 2-GSE84185 GSE84185-FluoxetineVsControlForStressedResponderInDentateGyrus 3-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 4-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.96: Alphabetically-sorted genes significant in at least one comparison (p-value &lt; 0.05 and pvalue rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.97: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-2-RatFluoxetineVsControlForStressed.html", "", " 4.3.2.2 Rat Stress Alone VS Stress Fluoxetine in Dentate Gyrus This section corresponds to the second meta-analysis requested by El Chrif. Table 4.9: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 2-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 3-SRP131063 SRP131063-FluoxetineVsSalineForStressed Figure 4.98: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.99: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-3-RatMouseFluoxetineVsControlForStressed.html", "", " 4.3.2.3 Rat+Mouse Fluoxetine VS Control for Stressed in Dentate Gyrus This section corresponds to the first+second meta-analysis requested by El Chrif. Table 4.10: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE43261 GSE43261-FluoxetineResponderVsControl 2-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 3-GSE84185 GSE84185-FluoxetineVsControlForStressedResponderInDentateGyrus 4-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 5-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 6-SRP131063 SRP131063-FluoxetineVsSalineForStressed 7-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.100: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.101: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-4-MouseFluoxetineVsControlForNoStressed.html", "", " 4.3.2.4 Mouse Fluoxetine VS Control for NoStressed in Dentate Gyrus This section corresponds to the third meta-analysis requested by El Chrif. Note GSE54307 is only a 1 VS 1 comparison. Table 4.11: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE54307 GSE54307-FluoxetineVsVehicle 3-GSE6476 GSE6476-FluoxetineVsControl 4-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 5-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked Figure 4.102: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.103: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-5-RatFluoxetineVsControlForNoStressed.html", "", " 4.3.2.5 Rat Fluoxetine VS Control for NoStressed in Dentate Gyrus This section corresponds to the fourth meta-analysis requested by El Chrif. Table 4.12: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE42940 GSE42940-FluoxetineVsControl 2-SRP056481 SRP056481-FluoxetineVsMethylcellulose Figure 4.104: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.105: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-6-RatMouseFluoxetineVsControlForNoStressed.html", "", " 4.3.2.6 Rat+Mouse Fluoxetine VS Control for NoStressed in Dentate Gyrus Table 4.13: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE42940 GSE42940-FluoxetineVsControl 3-GSE54307 GSE54307-FluoxetineVsVehicle 4-GSE6476 GSE6476-FluoxetineVsControl 5-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 6-SRP056481 SRP056481-FluoxetineVsMethylcellulose 7-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked Figure 4.106: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.107: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "],["3-results-3-Integration-2-OriginalSpecie-7-RatMouseFluoxetineVsControlForStressedAndNoStress.html", "", " 4.3.2.7 Rat+Mouse Fluoxetine VS Control for Stressed and no stressed in Dentate Gyrus This section corresponds to the 4 meta-analysis requested by El Chrif. Table 4.14: Mapping between ids and designs used in the integration plots below design_ids designs 1-GSE118669 GSE118669-FluoxetineVsVehicle 2-GSE42940 GSE42940-FluoxetineVsControl 3-GSE43261 GSE43261-FluoxetineResponderVsControl 4-GSE54307 GSE54307-FluoxetineVsVehicle 5-GSE56028 GSE56028-FluoxetineVsUntreatedForStressed 6-GSE6476 GSE6476-FluoxetineVsControl 7-GSE84185 GSE84185-FluoxetineVsControlForNoStressedInDentateGyrus 8-GSE84185 GSE84185-FluoxetineVsControlForStressedResponderInDentateGyrus 9-SRP056481 SRP056481-FluoxetineVsMethylcellulose 10-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1NonShocked 11-SRP057486 SRP057486-FluoxetineVsVehicleForBrainCA1StressedSubset 12-SRP084288 SRP084288-FluoxetineVsModelOfDepressionWithTissueAsCovariate 13-SRP131063 SRP131063-FluoxetineVsSalineForStressed 14-Surget2009 Surget2009-FluoxetineVsSalineForStressedInDentateGyrus Figure 4.108: Alphabetically-sorted genes significant in at least one comparison (padj &lt; 0.05). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). The xlsx table with all genes is available here Figure 4.109: Consensus-sorted genes significant in at least one comparison (p-value &lt; 0.05 and p-value rank &lt; 301). + and  signs highlight respectively upregulated and downregulated genes (|logFoldChange| &gt; 0.1 and raw pvalue &lt; 0.05). Underlying table is available here "]]
